GAD-7 Anxiety Screening: Take It, Score It, Understand Your Results
The GAD-7 (Generalized Anxiety Disorder-7) is a brief 7-item self-report questionnaire used to screen for symptoms of anxiety over the past two weeks. Developed in 2006 by Spitzer and colleagues at the same research group that built the PHQ-9, it is one of the most widely used anxiety screeners in primary care worldwide. The GAD-7 takes about 3 minutes to complete, is offered free of charge as a public-domain instrument, and produces a single 0-21 severity score that helps a clinician decide whether further evaluation is warranted. The GAD-7 is a screening tool, not a diagnosis: results should be reviewed with a healthcare professional.
What is the GAD-7?
The GAD-7 (Generalized Anxiety Disorder-7) is a brief anxiety screening questionnaire developed in 2006 by Drs. Robert Spitzer, Kurt Kroenke, Janet Williams, and Bernd Löwe — the same research group that built the PHQ-9 depression screener. It was originally validated against structured psychiatric interviews to detect generalized anxiety disorder (GAD), but subsequent research has shown it also works as a sensitive screen for other common anxiety disorders including panic disorder, social anxiety disorder, and post-traumatic stress disorder. The GAD-7 is in the public domain, free to use, and has been translated into many languages.
What the GAD-7 measures
The GAD-7 measures how often, over the past two weeks, you have experienced seven core symptoms of anxiety: feeling nervous, anxious, or on edge; being unable to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it is hard to sit still; becoming easily annoyed or irritable; and feeling afraid as if something awful might happen. A final question asks how difficult these symptoms have made daily life — work, home tasks, or relationships. The 7 items map closely to the symptoms the DSM uses to define generalized anxiety disorder, which is why the GAD-7 functions both as a severity index and a diagnostic screen.
How the GAD-7 is administered
The GAD-7 is a self-report questionnaire that takes about 2 to 3 minutes to complete. Each of the 7 items asks 'Over the last two weeks, how often have you been bothered by [symptom]?' Response options are scored 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day). You can complete it on paper, on a screen, or have a clinician read the items aloud — research shows the format does not change the result. The two-week recall window keeps the score focused on your current state rather than long-term anxiety history.
Who uses the GAD-7
The GAD-7 is widely used in primary care, mental health specialty clinics, integrated behavioral health programs, and clinical research. The U.S. Preventive Services Task Force recommends that adults aged 64 and younger be screened for anxiety disorders in primary care, and the GAD-7 is one of the most commonly recommended instruments. Many electronic health-record systems include the GAD-7 alongside the PHQ-9 as a routine pre-visit screening pair — a practice often called the PHQ-9 / GAD-7 combo — because depression and anxiety frequently co-occur. The GAD-7 is also used by therapists to monitor anxiety severity over the course of treatment.
GAD-7 is a screening tool, not a diagnosis
The GAD-7 is a screening instrument — it can indicate whether further evaluation for an anxiety disorder is warranted, but it cannot diagnose generalized anxiety disorder or any other anxiety condition on its own. A high score suggests that a clinician should follow up with a comprehensive assessment that considers your medical history, life context, and any co-occurring conditions. A low GAD-7 score does not rule out anxiety or other mental-health concerns; if you are worried about your mental health, talk to a clinician regardless of your score. Severe anxiety can affect daily functioning and is treatable — early conversation with a clinician is the most useful next step.
How to score and interpret your results
The GAD-7 is scored by adding the response values across all seven items. Each item is rated 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day), producing a total score between 0 and 21. The total maps to a four-band severity scale that has been used in clinical practice since the instrument was developed.
GAD-7 severity bands
| Total score | Severity | Suggested next step |
|---|---|---|
| 0-4 | Minimal anxiety | No further screening typically indicated |
| 5-9 | Mild anxiety | Re-screen if symptoms persist or worsen |
| 10-14 | Moderate anxiety | Further evaluation by a clinician is warranted |
| 15-21 | Severe anxiety | Prompt clinical evaluation recommended |
A score of 10 or higher is the most widely cited cutoff for clinically significant anxiety symptoms and is the threshold at which the original developers recommended a more thorough assessment. The same cutoff was used by the U.S. Preventive Services Task Force in its 2023 evidence review supporting routine anxiety screening in adults.
It is important to read the score as a symptom-severity index, not a binary “positive or negative” verdict. A score of 9 is not meaningfully different from a score of 10 — the cutoff is a clinical convention that helps prioritize follow-up, not a sharp diagnostic boundary. The GAD-7 is a screening tool, not a diagnosis, and a single score in any band should be interpreted alongside symptom history, life context, and any co-occurring conditions.
If you have completed a PHQ-9 depression screener at the same time — a common pairing in primary care — share both scores with your clinician. Anxiety and depression frequently co-occur, and the two scores together give a more complete picture than either alone.
What a positive screen means — and what it doesn’t
A “positive” GAD-7 screen — typically a score of 10 or higher — means that your reported symptoms over the past two weeks fall within a range commonly seen in adults with an anxiety disorder, and that a clinician should follow up. It does not mean you have generalized anxiety disorder, panic disorder, social anxiety, or any other specific condition. A formal diagnosis depends on a comprehensive clinical assessment.
What the score cannot tell you
Several important distinctions are outside what the GAD-7 can capture:
- Which anxiety disorder. The GAD-7 was developed for generalized anxiety disorder, but research has shown it also flags panic disorder, social anxiety disorder, and post-traumatic stress disorder at meaningful rates. A positive screen does not tell you which of these (if any) applies.
- Whether the pattern is chronic. The GAD-7 asks about the past two weeks. The DSM definition of generalized anxiety disorder, by contrast, requires difficulty controlling worry on most days for at least six months, plus at least three other persistent symptoms — restlessness, fatigue, concentration difficulties, irritability, muscle tension, or sleep problems.
- What is causing your symptoms. Anxiety symptoms can stem from a mental-health condition, a physical condition such as thyroid problems or arrhythmia, the effects of caffeine, substances, or certain medications, or a normal response to severe life stress. The GAD-7 cannot tell these apart.
- Whether you have co-occurring depression. Anxiety and depression overlap heavily; only a paired depression screener such as the PHQ-9 can address this.
Treating a positive GAD-7 as a starting point for a conversation — not as a label — is the most useful framing. Many people who screen positive are dealing with a treatable condition, and many also have physical or contextual factors that a clinician can help untangle.
How accurate is the GAD-7?
Two large bodies of evidence describe how well the GAD-7 identifies anxiety disorders at the standard ≥10 cutoff. Both support the cutoff as clinically useful, and they describe the instrument’s performance from different angles.
Original Spitzer 2006 validation
The original validation study enrolled roughly 3,000 patients across 15 U.S. primary care clinics and compared GAD-7 self-reported scores against independent mental health professional diagnoses. At a cutoff of 10, the GAD-7 showed:
- Sensitivity: 89% (correctly identifies people with generalized anxiety disorder)
- Specificity: 82% (correctly excludes people without it)
- Cronbach’s alpha = 0.92 (high internal consistency)
- Test-retest intraclass correlation = 0.83 (stable across repeated administration)
- ROC area under the curve = 0.906 (excellent overall discrimination)
The same study also reported performance for other common anxiety disorders: panic disorder (74% sensitivity, 81% specificity), social anxiety disorder (72% sensitivity, 80% specificity), and post-traumatic stress disorder (66% sensitivity, 81% specificity). This is why the GAD-7 is often described as a broad anxiety screener rather than a GAD-specific one.
USPSTF 2023 pooled meta-analysis
When the U.S. Preventive Services Task Force conducted its 2023 evidence review across multiple primary-care studies, the pooled estimates at the same ≥10 cutoff landed at:
- Sensitivity: 0.79 (95% CI, 0.65-0.94)
- Specificity: 0.89 (95% CI, 0.83-0.94)
The shorter GAD-2 (the first two items of the GAD-7) at a cutoff of ≥3 showed pooled sensitivity of 0.81 (0.73-0.89) and specificity of 0.86 (0.83-0.90), making it a reasonable ultra-brief alternative when time is tight.
The Spitzer 2006 and USPSTF 2023 estimates differ slightly because pooled meta-analytic numbers across heterogeneous populations naturally settle at a different operating point than a single-study development sample. Both sets of numbers support using ≥10 as a practical threshold for “warrants a closer look”.
Limitations and considerations
The GAD-7 is a well-validated tool, but every screening instrument has boundaries. Understanding these helps you interpret your own score honestly and avoid over- or under-reading the result.
Things the GAD-7 cannot do
- It cannot distinguish among anxiety disorders. A high score can reflect generalized anxiety, panic, social anxiety, or PTSD — the items overlap. Sorting out which one (if any) requires a clinical interview.
- It is anchored to two weeks. Symptoms that flare outside the two-week window, or chronic patterns that have been present for years but are quiet at the moment of testing, may not be reflected in your score.
- It depends on honest self-report. Recall errors, reluctance to disclose, or the way the form is worded all affect the result. Self-report instruments cannot correct for this on their own.
- It does not measure suicidality. The GAD-7 items ask only about anxiety symptoms — they do not address suicidal thoughts. A low score on the GAD-7 therefore does not rule out crisis-level distress, and a high score does not by itself indicate suicide risk. Suicidal thoughts can accompany anxiety disorders and require separate assessment.
- Evidence is thinner in adults 65 and older. The USPSTF gave a Grade I (“insufficient evidence”) statement for routine anxiety screening in this age group in 2023, citing inadequate data on tool accuracy and treatment effectiveness in older adults.
What it is not designed for
The GAD-7 is not a stand-alone diagnostic tool. The USPSTF specifically emphasizes that a positive screen requires further diagnostic assessment before any treatment decisions are made. It is also not validated as a pediatric instrument — its evidence base is in adults, and the USPSTF screening recommendation applies to adults aged 19-64.
Anxiety presentations in children, adolescents, and older adults can differ enough that adult-validated cutoffs may not transfer cleanly. Across primary care, anxiety also often presents through somatic complaints rather than as worry — only about 13% of patients later diagnosed with generalized anxiety disorder report anxiety as their chief complaint, while nearly half present with somatic concerns.
What to do with your results
What happens next depends on your score band and on the context around it. The GAD-7 is a screening tool, not a diagnosis — the goal of taking it is to decide whether to start a conversation with a clinician, not to self-treat.
Minimal score (0-4)
A score in this range suggests your anxiety symptoms over the past two weeks were minimal. No specific follow-up is usually indicated. If symptoms develop or worsen later, the GAD-7 can be re-administered at any time — there is no waiting period.
Mild score (5-9)
A mild score generally calls for noticing whether symptoms settle, persist, or grow over the next few weeks. Reviewing factors that can worsen anxiety — caffeine intake, sleep, and certain medications — can be useful, since NIMH and MedlinePlus both note these as common modifiers. If symptoms persist or affect daily life, raise the score with your primary care provider.
Moderate or severe score (10-21)
A moderate or severe score warrants prompt follow-up with a clinician. Useful steps:
- Bring your printed or written GAD-7 score, the date you completed it, and a brief note of what was happening in your life at the time.
- Be ready to describe how long symptoms have been present — the DSM threshold for generalized anxiety disorder is six months or more of difficulty controlling worry.
- Note any physical symptoms (headaches, muscle aches, stomach discomfort, sleep problems) — these are part of how anxiety often shows up in primary care and can change the assessment.
- Mention any co-occurring depression symptoms; many primary-care visits pair the GAD-7 with the PHQ-9 for this reason.
About treatment
Effective treatments for anxiety disorders exist. Psychological interventions such as cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) are associated with moderate-magnitude benefit for reducing anxiety symptoms in adults. Several medication classes are also used; the right combination depends on the specific diagnosis, other health conditions, pregnancy or postpartum status, and personal preference, and should be discussed with a healthcare provider.
Frequently asked questions
What is a “normal” GAD-7 score?
Scores of 0-4 are classified as minimal anxiety and are the most common result in people without an anxiety disorder. There is no single “normal” number — even a score of 5-9 (mild) is common and often does not warrant clinical follow-up unless symptoms persist. A score of 10 or higher is the threshold at which the original developers recommended further evaluation.
Is the GAD-7 free to use?
Yes. The GAD-7 is in the public domain and free to use, copy, translate, and distribute without permission. The instrument and its many translations are available directly from the PHQ Screeners website maintained by the original development group. No license fee, registration, or attribution payment is required.
How is the GAD-7 different from the GAD-2?
The GAD-2 is the first two items of the GAD-7 — “feeling nervous, anxious, or on edge” and “not being able to stop or control worrying” — scored 0-6. It is designed for ultra-brief screening when time is limited. At a cutoff of ≥3, the GAD-2 has pooled sensitivity of 0.81 and specificity of 0.86. The full GAD-7 is preferred when feasible because it captures more symptom detail and gives a finer severity grade. See our GAD-2 / PHQ-2 ultra-brief screening page for more.
Can I take the GAD-7 online?
Yes. The GAD-7 is a self-report instrument that works equally well on paper or on a screen, and is freely distributed for online use. Taking it online produces the same 0-21 score and the same severity bands, but it does not replace clinical follow-up — share any positive result with a healthcare provider.
How is the GAD-7 different from the PHQ-9?
The PHQ-9 screens for depression symptoms, while the GAD-7 screens for anxiety symptoms. Both were developed by the same research team and use a 0-3 response scale over a two-week recall window. The two are often given together in primary care because depression and anxiety frequently co-occur.
Should I take the GAD-7 if I already have an anxiety diagnosis?
Yes, with a different purpose: in that case the GAD-7 functions as a severity-tracking tool rather than a screener. Because of its strong test-retest reliability, clinicians can re-administer it during follow-up visits to monitor whether symptoms are improving with treatment. Discuss the timing with the provider managing your care.
Does a low GAD-7 score mean I don’t have anxiety?
No. A low score means your reported symptoms over the past two weeks fall in the minimal range. But symptoms outside that window, symptoms you did not disclose, or symptoms of a different anxiety disorder that the GAD-7 does not capture as fully may still be present. The GAD-7 is a screening tool, not a diagnosis. If you are worried about your mental health, talk with a clinician regardless of the score.
When to seek immediate help
Severe anxiety can co-occur with suicidal thoughts, and the GAD-7 by design does not measure suicidality. A low GAD-7 score does not rule out a mental-health crisis, and a high score is not by itself a crisis indicator — what matters is what you are experiencing right now.
If you are in the United States and having thoughts of suicide or self-harm, do not wait for an appointment. Reach out immediately:
- Call or text 988 to connect with the Suicide & Crisis Lifeline, a free and confidential service.
- Chat online at 988lifeline.org if you would rather type than talk.
- Call 911 for any life-threatening situation.
Other situations that need prompt attention
In addition to thoughts of self-harm, some patterns warrant same-day or same-week contact with a clinician rather than a routine appointment:
- A sudden, sharp increase in anxiety symptoms — for example, a jump from a previous mild score into the severe range over a short period.
- Anxiety severe enough that you are unable to perform basic daily activities such as going to work, caring for children, eating, or sleeping.
- New panic-like episodes — sudden, intense fear coming on rapidly and lasting several minutes or longer, which are characteristic of panic disorder.
- Anxiety combined with substance use to cope, which is a recognized comorbidity pattern that can worsen the underlying condition.
- Co-occurring symptoms of depression such as persistent low mood or loss of interest, especially if a PHQ-9 also shows moderate or severe scores. Suicidal thoughts may accompany GAD and require separate assessment.
Reach out to your primary care provider or a mental-health professional. NIMH also points to SAMHSA’s treatment locator as a public referral resource for people without an existing provider. Treatment for anxiety disorders is available and effective for many people, and starting the conversation does not commit you to any particular path.